wedelolactone and Skin-Neoplasms

wedelolactone has been researched along with Skin-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for wedelolactone and Skin-Neoplasms

ArticleYear
Wedelolactone mitigates UVB induced oxidative stress, inflammation and early tumor promotion events in murine skin: plausible role of NFkB pathway.
    European journal of pharmacology, 2016, Sep-05, Volume: 786

    UVB (Ultra-violet B) radiation is one of the major etiological factors in various dermal pathology viz. dermatitis, actinic folliculitis, solar urticaria, psoriasis and cancer among many others. UVB causes toxic manifestation in tissues by inciting inflammatory and tumor promoting events. We have designed this study to assess the anti-inflammatory and anti-tumor promotion effect of Wedelolactone (WDL) a specific IKK inhibitor. Results indicate significant restoration of anti-oxidative enzymes due to WDL treatments. We also found that WDL was effective in mitigating inflammatory markers consisting of MPO (myeloperoxidase), Mast cells trafficking, Langerhans cells suppression and COX 2 expression up regulation due to UVB exposure. We also deduce that WDL presented a promising intervention in attenuating early tumor promotion events caused by UVB exposure as indicated by the results of ODC (Ornithine Decarboxylase), Thymidine assay, Vimentin and VEGF (Vascular-endothelial growth factor) expression. This study was able to provide substantial cues for the therapeutic ability of Wedelolactone against inflammatory and tumor promoting events in murine skin depicting plausible role of NFkB pathway.

    Topics: Animals; Carcinogenesis; Cell Communication; Cell Transformation, Neoplastic; Coumarins; DNA; Gene Expression Regulation; Inflammation; Male; Mice; Neovascularization, Pathologic; Oxidative Stress; Polyamines; Skin; Skin Neoplasms; Transcription Factor RelA; Ultraviolet Rays

2016